Testimonials from DxPx exhibitors

Testimonials from our exhibitors​

Get a taste of what DxPx has in store for you, through the eyes of our past exhibitors!

sponsor lino biotech

Life Science Tools

Label-free biosensoring directly from crude samples

lino Biotech is the world´s only provider of Focal Molography – an entirely new method for measuring molecular interactions in living cells or crude biological samples. The broadly patented technology offers label-free detection assays while eliminating signal disturbances due to temperature changes or non-specific binding.

Dr. Mirko Stange
Mirko Stange, CEO

1. What is it you are looking for when going to partnering conferences?

  • Meeting new investors, potential new clients, or multipliers
  • Promoting my own startup
  • Follow-up meetings or face-to-face
dxpx eu startup citz ticket shop

2. What is your company all about?

lino Biotech was incorporated in Zürich, Switzerland, in March 2020 after 10 years of research as spin-out from Roche Diagnostics. We have developed a reagent-free method for measuring molecular interactions in living cells or crude biological samples called focal Molography. With our first products, we aim to lower the cost of drug discovery and cell and gene therapies and make them more cost effective and accessible for a broader patient population by offering access to a unique analytical technology to optimize production processes at highest quality level. Our team consists of highly qualified experts with different backgrounds in Biochemistry, Biophysics, Biomedical Engineering, Software Engineering and Business Development, all with the same goal.

3. Why did you found your company?

We can detect multiple target-types simultaneously – without purification – to make analytics faster and more cost-effective. Our sensing principle is based on light interference caused by an imprinted molecular grating in chip. Cell and gene therapies generally face the issue of a long product quality control with high production cost. That´s why our biosensors therefore enable much faster and more accurate characterization of cell therapy products while at the same time helping the manufacturer to substantially reduce production cost. We started with a founder team of three people covering business and scientific aspects with great support of ETH Zurich and Roche Basel, then expanded our team.
lino

4. Waht is your current fundraising strategy?

We can detect multiple target-types simultaneously – without purification – to make analytics faster and more cost-effective. Our sensing principle is based on light interference caused by an imprinted molecular grating in chip. Cell and gene therapies generally face the issue of a long product quality control with high production cost. That´s why our biosensors therefore enable much faster and more accurate characterization of cell therapy products while at the same time helping the manufacturer to substantially reduce production cost. We started with a founder team of three people covering business and scientific aspects with great support of ETH Zurich and Roche Basel, then expanded our team.

5. What were your biggest lessons learned and biggest accomplishments?

One of the biggest accomplishments was definitely establishing a great team around our trend-setting technology, we also solved multiple open questions regarding a scalable production of our sensor consumables and designed our first industrial instrument. Challenges arising from the COVID pandemic and other ongoing crises, stopped or slowed us down in regards of closing our Series A and with suppliers for our materials.

6. Have you attended DxPx previously?

We (so far) had attended DxPx EU and US in 2021, and the DxPx US Conference this year, and are very convinced of the whole concept!
Having partnering cubicles simplifies meeting investors and clients in a quieter atmosphere than is otherwise the case at conferences and the whole networking tool is much more convenient and it is impressive how many VC are present.

Returning to Düsseldorf, Germany – 15-16 November 2022 for 2-days onsite event of effective networking opportunities. Join DxPx EU to discuss M&A, licensing and financing opportunities, meet old acquaintances and make new international contacts.

Meet investors and industry partners who share your love for Diagnostics, Digital Health, Precision Medicine & Life Science Tools. 

  • 500+ participants with 100+ VC, corporate VC and other investors expected: All sharing your interest in life science outside therapeutics and biotech
  • 40 exhibitors: Selected innovations featured at our innovation pavilion
  • 12 Panels: Featuring industry experts and investors sharing their knowledge
  • 1 Pitch award: 8 companies that are carefully selected by over 30 VCs prior to the event will present their business and compete for funding of up to 2 Mio US
… and our famous rooftop reception on day 2 of the event.

“The cooperation of AACC as largest diagnostics trade fair in the world with the DxPx is a clear win for us. We look forward to participating again as partner and juror for the 42plus1 Pitch Award.”

qiagen logo sponsordxpx eu conference
Sebastian Swienty

Sebastian Swienty

Senior Director

“Thanks for this great event. I truly enjoyed it. The format facilitated deep and very efficient interactions with potential partners.”

sponsor roche
Dr. Babette Güldenpfennig

Dr. Babette Güldenpfennig

Head of Global Licensing